{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-011733","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.544113+00:00","generated_at":"2026-05-27T00:13:21.086946+00:00","sec_items":["1.01","1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio licenses MissionEB data, plans BLA for CORDStrom in pediatric RDEB","bullets":["Plans to submit BLA in 2025 for CORDStrom to treat pediatric RDEB, supported by positive Phase 2 MissionEB data in 30 patients.","Licensed exclusive commercial rights to MissionEB data from Great Ormond Street Hospital for £250k upfront and up to £6M milestone on first marketing authorization.","FDA granted Rare Pediatric Disease Designation (RPDD) Dec 2024 and Orphan Drug Designation (ODD) Jan 2025, preserving PRV eligibility.","CORDStrom well tolerated; severe RDEB patients had >27% sustained itch reduction at 6 months; younger and intermediate patients showed skin and pain improvements.","Terminated existing SVB loan agreement with zero balance and no penalty; no financial impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-011733","json":"https://secwatch.observer/filing/0001213900-25-011733.json","markdown":"https://secwatch.observer/filing/0001213900-25-011733.md","text":"https://secwatch.observer/filing/0001213900-25-011733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/0001213900-25-011733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea0230277-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:13:21.086946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}